Cellular therapies in acute lymphoblastic leukemia

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 4, 2009, Pages 375-382

  Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Adoptive cell therapy; Chimeric antigen receptor; Donor lymphocyte infusion; Hematopoietic stem cell transplantation; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; HUMAN; NATURAL KILLER CELL; REVIEW; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ADOPTIVE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES; TISSUE DONORS;

EID: 68649111623     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 354(2):166-178.
2. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet (2008) 371 (9617):1030-1043.
3. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK et al: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2007) 109(3):944-950.
4. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol (2005) 131(5):579-587.
5. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O et al: Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 21(9):1907-1914.
6. Porter DL, Antin JH: The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med (1999) 50:369-386.
7. Larson R: Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant (2008) 42 (Suppl 1) :S18-S24.
8. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: An evidence-based review. Biol Blood Marrow Transplant (2006) 12:1-30.
9. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, Lepage E, Thomas X, Fière D: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am (2000) 14(6):1353-1366.
10. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A et al: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol (2004) 22(20):4075-4086.
11. Yanada M, Matsuo K, Suzuki T, Naoe T: Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer (2006) 106(12):2657-2663.
12. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood (2008) 111(4):1827-1833.
13. Challenges the standard-of-care in patients with ALL with respect to allo-HSCT, demonstrating improved outcomes in patients with standard, but not high-risk, ALL.
14. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA et al: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica (2005) 90(10):1346-1356.
15. Similar to reference [12], this study contradicts the standard-of-care for patients with high-risk ALL, challenging the notion that high-risk patients have an improved outcome following allo-HSCT.
16. Chim CS, Lie AK, Liang R, Au WY, Kwong YL: Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: Favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant (2007) 40(4):339-347.
17. Dahlke J, Kröger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, Waschke O, Schieder H, Renges H, Krüger W, Kruell A et al: Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant (2006) 37(2):155-163.
18. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A et al: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. J Clin Oncol (2004) 22(14):2816-2825.
19. Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS et al: The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2009) 113(13):3110-3118.
20. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI et al: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 351(22):2265-2275.
21. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, Jacobsen N, Ruutu T, de Lima M, Finke J, Frassoni F et al: Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 351(22):2276-2285.
22. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, Uchimaru K, Tojo A, Shirafuji N, Kodo H et al: Singleinstitute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood (2004) 104(12):3813-3820.
23. Kumar P, Defor TE, Brunstein C, Barker JN, Wagner JE, Weisdorf DJ, Burns LJ: Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: Impact of donor source on survival. Biol Blood Marrow Transplant (2008) 14(12):1394-1400.
24. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H et al: Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood (2009) 113(8):1631-1638.
25. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ: Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood (2009) 113(13):2902-2905.
26. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: Experience in Europe and the United States. Bone Marrow Transplant (2008) 41(5):473-481.
27. An outstanding review of the development of haploidentical donor allo-HSCT into a feasible alternative approach for patients lacking suitably matched HSCT donors.
28. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C et al: Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood (1994) 84(11):3948-3955.
29. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y et al: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med (1998) 339(17):1186-1193.
30. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T et al: Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 23(15):3447-3454.
31. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E et al: A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: A risk factor analysis of outcomes for patients in remission at transplantation. Blood (2008) 112(9):3574- 3581.
32. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant (2009) 15(2):257-265.
33. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol (2009) 46(1):64-75.
34. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 86(5):2041-2050.
35. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ: Graft-versus-leukemia reactions in allogeneic chimeras. Blood (2004) 103(3):767-776.
36. Loren AW, Porter DL: Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant (2008) 41(5):483-493.
37. Choi SJ, Lee JH, Lee JH, Kim S, Lee YS, Seol M, Ryu SG, Lee JS, Kim WK, Jang S, Park CJ et al: Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A prospective study. Bone Marrow Transplant (2005) 36(2):163-169.
38. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P: Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant (2000) 26(5):511-516.
39. Chang CS, Lin SF, Liu TC, Huang SM, Chen TP: Donor leukocyte infusion as salvage therapy in an adult with relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation. J Formos Med Assoc (1998) 97(1):55-58.
40. Patriarca F, Sperotto A, Skert C, Damiani D, Prosdocimo S, Fanin R: Successful treatment of hematological and extramedullary relapse of MLL-positive acute lymphoblastic leukemia after bone marrow transplantation using donor leukocyte infusion. Ann Hematol (2004) 83(10):667-669.
41. Yazaki M, Andoh M, Ito T, Ohno T, Wada Y: Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion. Bone Marrow Transplant (1997) 19(4):393-394.
42. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S et al: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood (2006) 107(4):1325-1331.
43. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K et al: Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics (2000) 51(2):99-107.
44. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol (2000) 164(4): 1873-1880.
45. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ: Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood (2007) 110(6):1924-1932.
46. Brentjens RJ: Novel approaches to immunotherapy for B-cell malignancies. Curr Oncol Rep (2004) 6(5):339-347.
47. Sadelain M, Brentjens R, Rivière I: The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol (2009) 21(2):215-223.
48. An updated review on the status of adoptive T-cell therapy for the treatment of cancer using CAR-engineered T-cells.
49. Sadelain M, Rivière I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3(1):35-45.
50. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279-286.
51. First reported study demonstrating in vivo efficacy of CD19-targeted CAR+ T-cells.
52. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M: Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 13 (18 Pt 1) :5426-5435.
53. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC: Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis (2004) 33(1):83-89.
54. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC: Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood (2005) 105(4):1622- 1631.
55. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC: T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2003) 101(4):1637-1644.
56. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 18(4):676-684.
57. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ: CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 66(22):10995-11004.
58. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK: Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia (2006) 20(10):1819-1828.
59. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK: Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood (2002) 99(6):2009-2016.
60. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M et al: Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 32(3):169-180.
61. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ et al: Differentiation of naïve cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood (2006) 107(7):2643-2652.
62. Savoldo B, Mickllethwaite K, Cooper L, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G: Monoculture-derived T lymphocytes providing multiple virus specificity and anti-leukemia activity for recipients of hematopoietic stem cells or umbilical cord blood transplants. Blood (2008) 112:Abs 3909.
63. Grzywacz B, Miller JS, Verneris MR: Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol (2008) 21(3):467-483.
64. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295 (5562):2097-2100.
65. First report demonstrating the clinical application of KIR-mismatch in allo-HSCT outcomes in acute leukemias, demonstrating the potential of adoptive transfer of KIR-mismatched NK cells as an alternative therapeutic approach for relapsed leukemias.
66. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP et al: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GvHD) following unrelated donor allogeneic HCT. Blood (2007) 109(11):5058-5061.
67. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ et al: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-3057.
68. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M et al: Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 143(5):641-653.
69. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R: Clinical-grade ex vivo - expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 11(3):341-355.
70. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 69(9):4010-4017.
71. Imai C, Iwamoto S, Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 106(1):376-383.
72. Preclinical studies demonstrating the efficacy and feasibility of CAR-modified NK cells to target and lyse otherwise NK cell-refractory ALL tumor cell lines, providing the rationale for a pending clinical trial using genetically modified NK cells targeted to CD19 in patients with ALL; the first such trial of its kind.